X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs WYETH LTD - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD WYETH LTD ALEMBIC LTD/
WYETH LTD
 
P/E (TTM) x 56.2 27.7 202.9% View Chart
P/BV x 2.3 5.3 43.9% View Chart
Dividend Yield % 0.4 1.3 34.1%  

Financials

 ALEMBIC LTD   WYETH LTD
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
WYETH LTD
Mar-13
ALEMBIC LTD/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs721,044 6.9%   
Low Rs34818 4.1%   
Sales per share (Unadj.) Rs4.7298.6 1.6%  
Earnings per share (Unadj.) Rs6.157.2 10.7%  
Cash flow per share (Unadj.) Rs6.258.4 10.7%  
Dividends per share (Unadj.) Rs0.2017.00 1.2%  
Dividend yield (eoy) %0.41.8 20.7%  
Book value per share (Unadj.) Rs40.7249.5 16.3%  
Shares outstanding (eoy) m267.0322.72 1,175.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.33.1 361.2%   
Avg P/E ratio x8.716.3 53.3%  
P/CF ratio (eoy) x8.515.9 53.2%  
Price / Book Value ratio x1.33.7 34.9%  
Dividend payout %3.329.7 11.0%   
Avg Mkt Cap Rs m14,13921,157 66.8%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m207400 51.9%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m1,2556,783 18.5%  
Other income Rs m370353 105.0%   
Total revenues Rs m1,6257,136 22.8%   
Gross profit Rs m1111,617 6.9%  
Depreciation Rs m3827 142.1%   
Interest Rs m26 30.9%   
Profit before tax Rs m4421,938 22.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m24632 3.8%   
Profit after tax Rs m1,6301,301 125.3%  
Gross profit margin %8.923.8 37.1%  
Effective tax rate %5.432.6 16.6%   
Net profit margin %129.819.2 677.3%  
BALANCE SHEET DATA
Current assets Rs m1,8676,984 26.7%   
Current liabilities Rs m5912,056 28.8%   
Net working cap to sales %101.672.6 139.9%  
Current ratio x3.23.4 93.0%  
Inventory Days Days9499 95.0%  
Debtors Days Days7424 307.2%  
Net fixed assets Rs m1,791244 733.1%   
Share capital Rs m534227 235.1%   
"Free" reserves Rs m10,3245,441 189.7%   
Net worth Rs m10,8585,668 191.6%   
Long term debt Rs m4125 164.8%   
Total assets Rs m11,5917,901 146.7%  
Interest coverage x260.9353.3 73.8%   
Debt to equity ratio x00 86.0%  
Sales to assets ratio x0.10.9 12.6%   
Return on assets %14.116.5 85.2%  
Return on equity %15.022.9 65.4%  
Return on capital %15.234.0 44.6%  
Exports to sales %1.50.2 708.4%   
Imports to sales %21.036.3 57.7%   
Exports (fob) Rs m1915 131.1%   
Imports (cif) Rs m2632,465 10.7%   
Fx inflow Rs m1915 127.6%   
Fx outflow Rs m2642,677 9.9%   
Net fx Rs m-244-2,662 9.2%   
CASH FLOW
From Operations Rs m236923 25.5%  
From Investments Rs m-224317 -70.7%  
From Financial Activity Rs m-27-481 5.5%  
Net Cashflow Rs m-15759 -1.9%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.2 11.3 1.8%  
FIIs % 9.7 7.2 134.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 30.4 85.9%  
Shareholders   54,701 21,978 248.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   DR. DATSONS LABS  STRIDES SHASUN LTD  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY18); Net Profit Up 64.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC LTD has posted a net profit of Rs 46 m (up 64.9% YoY). Sales on the other hand came in at Rs 332 m (up 0.9% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Aug 17, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - PLETHICO PHARMA COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS